|
Update on Diagnosis and Prognostic Evaluation of MDS
Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop...
An interesting report on the state of art for MDS diagnosis from Luekemia Research. It's free on CME today when you log in or register as required. 
http://www.lrjournal.com/article/S01...537-6/fulltext
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%  ) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
|